Key result
LVRI ≥7.5 predicts ~150% higher ventricular tachyarrhythmia risk in nonischemic DCM with LVEF <35%.
Why the study?
In DCM patients with LVEF <35%, isolated LGE may not differ between those with and without adverse outcomes, and the predictive value of LV remodeling index for ventricular tachyarrhythmia remains unclear.
Does a left ventricular remodeling index (LVRI) ≥7.5 predict ventricular tachyarrhythmia in patients with nonischemic dilated cardiomyopathy and LVEF <35%?
Does a left ventricular remodeling index (LVRI) ≥7.5 predict ventricular tachyarrhythmia in patients with nonischemic dilated cardiomyopathy and LVEF <35%?
In patients with nonischemic dilated cardiomyopathy and LVEF <35%, a CMR-derived left ventricular remodeling index ≥7.5 is an independent predictor of lethal ventricular tachyarrhythmias.
Background Myocardial fibrosis assessed by cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) imaging has emerged as a powerful predictor for sudden cardiac death (SCD) in dilated cardiomyopathy (DCM). However, in the cohort of DCM patients with LVEF <35%, isolated LGE may not exhibit significant difference between those with and without adverse outcomes. In such circumstances, morphological parameters may provide additional prognostic value for DCM patients with left ventricular ejection fraction (LVEF) <35%. The predictive value of LV remodeling index (LVRI), a novel geometry parameter derived from CMR, for ventricular tachyarrhythmia (VTA) in this population remains unclear. Purpose To explore the predictive value of LVRI for VTA in patients with nonischemic DCM with LVEF <35%. Methods In this retrospective single-center study, consecutive DCM patients with LVEF <35% (n=271) who underwent CMR imaging were followed up. The study endpoint was VTA, a composite of sudden cardiac death or major ventricular arrhythmias. The newly derived LVRI was defined as the cubic root of the LV end-diastolic volume divided by the maximal LV wall thickness. Competing risk regression analysis and Kaplan-Meier analysis were used to evaluate the association of LVRI with VTA. Results During a median follow-up of 71 months (interquartile range: 17–134 months), 35 (12.9%, mean age 46.7 years, 27 males) participants reached VTA events. The presence of late gadolinium enhancement (LGE) (62.9% vs. 60.2%, p = .761) and LVEF (23.3±6 vs. 21.9±10.3, p = .197) were not significantly different between the patients with and without endpoint. Kaplan-Meier curve analysis showed that participants with LVRI ≥7.5 were more likely to experience VTA (p < .0001). In the multiple competing risk analysis, when heart transplantation and heart failure (HF)-related death were counted as competing risks, LVRI ≥7.5 (HR, 2.496; 95% CI: 1.213-5.138; p = .013) was observed as an independent predictor of VTA after adjusting for age, sex and left bundle branch block. Conclusion For patients with nonischemic DCM with LVEF <35%, CMR-assessed LVRI ≥7.5 was associated with lethal VTA events.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2025) studied this question. In nonischemic DCM patients with LVEF <35%, LVRI ≥7.5 predicted ventricular tachyarrhythmia with HR 2.5 (95% CI 1.21-5.14, p=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: